Cargando…

Celiac disease serology and gut microbiome following proton pump inhibitor treatment

BACKGROUND: Celiac disease is an autoimmune enteropathy characterized by an aberrant immune response to ingested gluten in genetically predisposed individuals. Studies have pointed to a rising prevalence of celiac disease in recent decades. Changes in diet and use of medication that may impact the g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jang, Sophie, Lebwohl, Benjamin, Abrams, Julian A., Green, Peter H.R., Freedberg, Daniel E., Alaedini, Armin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458245/ https://www.ncbi.nlm.nih.gov/pubmed/32871870 http://dx.doi.org/10.1097/MD.0000000000021488

Ejemplares similares

Use of proton pump inhibitors for the risk of gastric cancer
por: Gao, Huiqin, et al.
Publicado: (2022)

A review of the long-term use of proton pump inhibitors and risk of celiac disease in the context of HLA-DQ2 and HLA-DQ8 genetic predisposition
por: McMillan, Alexandra, et al.
Publicado: (2023)

Celiac disease serology and gut microbiome following protein pump inhibitor treatment: Erratum
Publicado: (2020)

Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis
por: Bian, Jin, et al.
Publicado: (2017)

Rebamipide Plus Proton Pump Inhibitor Versus Proton Pump Inhibitor Alone in the Treatment of Endoscopic Submucosal Dissection-Induced Gastric Ulcer: Retracted: A Meta-Analysis of Randomized Controlled Trials
por: Xiong, Ji, et al.
Publicado: (2014)

Proton pump inhibitor use is associated with a variety of infections in patients with liver cirrhosis
por: Labenz, Christian, et al.
Publicado: (2020)

Serological Screening for Celiac Disease in Adult Chinese Patients With Diarrhea Predominant Irritable Bowel Syndrome
por: Wang, Hongling, et al.
Publicado: (2015)

Lack of Effect of Gluten Challenge on Fecal Microbiome in Patients With Celiac Disease and Non-Celiac Gluten Sensitivity
por: Nobel, Yael R., et al.
Publicado: (2021)

Borrelia infection and risk of celiac disease
por: Alaedini, Armin, et al.
Publicado: (2017)

Effectiveness and safety of proton pump inhibitors for treating acute pancreatitis: A protocol for systematic review and meta analysis
por: Cheng, Tao, et al.
Publicado: (2021)

Influence of individual proton pump inhibitors on clinical outcomes in patients receiving clopidogrel following percutaneous coronary intervention
por: Lee, Dongyoung, et al.
Publicado: (2021)

Proton pump inhibitors alter the composition of the gut microbiota
por: Jackson, Matthew A, et al.
Publicado: (2016)

Role of altered esophageal intraluminal baseline impedance levels in patients with gatroesophageal reflux disease refractory to proton pump inhibitors
por: Jiang, Liuqin, et al.
Publicado: (2016)

Stretta procedure versus proton pump inhibitors for the treatment of nonerosive reflux disease: A 6-month follow-up
por: He, Suyu, et al.
Publicado: (2020)

Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis
por: Li, Mei-Juan, et al.
Publicado: (2017)

Efficacy of vonoprazan for initial and maintenance therapy in reflux esophagitis, nonerosive esophagitis, and proton pump inhibitor-resistant gastroesophageal reflux disease
por: Gotoh, Yasuhiko, et al.
Publicado: (2020)

The prognosis and incidence of hepatic encephalopathy of patients with liver cirrhosis treated with proton pump inhibitors: A multicenter retrospective study in Japan
por: Sakamaki, Akira, et al.
Publicado: (2021)

Proton pump inhibitors affect the gut microbiome
por: Imhann, Floris, et al.
Publicado: (2016)

Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis
por: Yang, Sensen, et al.
Publicado: (2022)

Proton Pump Inhibitor Therapy Is Associated With Reduction of Early Bleeding Risk After Prophylactic Endoscopic Variceal Band Ligation: A Retrospective Cohort Study
por: Kang, Seong Hee, et al.
Publicado: (2016)

Cost-effectiveness and clinical outcomes of intermittent/continuous proton pump inhibitors infusion in high bleeding risk of ulcers: A retrospective observational cohort study
por: Hsieh, Hui-Hsia, et al.
Publicado: (2021)

Whether long-term use of proton pump inhibitor increases the risk of precancerous lesions in the stomach: A systematic review and meta-analysis of randomized controlled trials
por: Lv, Fangyi, et al.
Publicado: (2023)

Vonoprazan vs proton pump inhibitors in treating post-endoscopic submucosal dissection ulcers and preventing bleeding: A meta-analysis of randomized controlled trials and observational studies
por: Martin,, et al.
Publicado: (2020)

How is gut microbiome of patients with familial adenomatous polyposis different from healthy people?
por: Kim, Jae Hyun, et al.
Publicado: (2022)

Lack of Serologic Evidence to Link IgA Nephropathy with Celiac Disease or Immune Reactivity to Gluten
por: Moeller, Sina, et al.
Publicado: (2014)

Autoantibodies in the Extraintestinal Manifestations of Celiac Disease
por: Yu, Xuechen B., et al.
Publicado: (2018)

Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: A systematic review and meta-analysis
por: Huang, Long, et al.
Publicado: (2022)

Virological and serological features of acute hepatitis B in adults
por: Du, Xiaofei, et al.
Publicado: (2017)

Are gastric hyperplastic polyps an additional manifestation in celiac disease?: Results from a retrospective study
por: Dore, Maria Pina, et al.
Publicado: (2017)

Diagnostic dilemma of celiac disease presenting with weight loss and secondary amenorrhea: A case report
por: Mumtaz, Arif, et al.
Publicado: (2022)

Ratio of Spleen Diameter to Red Blood Cell Distribution Width: A Novel Indicator for Celiac Disease
por: Balaban, Daniel Vasile, et al.
Publicado: (2015)

Distal Pancreatectomy With En Bloc Celiac Axis Resection for Locally Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Gong, Haibing, et al.
Publicado: (2016)

Stromal cell-derived factor-1 as a serologic biomarker for the diagnosis of colon ischemia with chronic cardiovascular disease
por: Kim, Ka Young, et al.
Publicado: (2020)

The role of soluble tumor necrosis factor like weak inducer of apoptosis and interleukin-17A in the etiopathogenesis of celiac disease: A cross-sectional study
por: Yuksel, Mahmut, et al.
Publicado: (2016)

Appropriateness of Proton Pump Inhibitor Prescription Evaluated by Using Serological Markers
por: Russo, Michele, et al.
Publicado: (2023)

Proton pump inhibitors induce changes in the gut microbiome composition of systemic lupus erythematosus patients
por: Li, Xian-Bao, et al.
Publicado: (2022)

Effect of proton pump inhibitors in infants with esophageal atresia on the gut microbiome: a pilot cohort
por: Brusselaers, Nele, et al.
Publicado: (2022)

Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis
por: Horvath, Angela, et al.
Publicado: (2019)

An International Reporting Registry of Patients With Celiac Disease and COVID-19: Initial Results From SECURE-CELIAC
por: Uche-Anya, Eugenia, et al.
Publicado: (2021)

Fr228 AN INTERNATIONAL REPORTING REGISTRY OF PATIENTS WITH CELIAC DISEASE AND COVID-19: INITIAL RESULTS FROM SECURE-CELIAC
por: Uche-Anya, Eugenia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q5olops6vfc759d3jtnam5u6ar